Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Posters/Exhibits/Break > Session
Posters/Exhibits/Break
Presentations
A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS | |||||
|
(602) ASSOCIATION OF PEAK GAMMA PRIME FIBRINOGEN LEVELS WITH OUTCOMES IN TRAUMA PATIENTS Lydia Buzzard1, Ali Oran2, Martin Schreiber3, David Farrell1. 1Donald D. Trunkey Center for Civilian and Combat Casualty Care, Department of Surgery, Oregon Health & Science University, Portland, OR, USA 2Department of Surgery, Oregon Health & Science University, Portland, OR, USA 3Uniformed Services University of the Health Sciences, Bethesda, MD, USA |
||||
|
(603) RELEVANCE OF ANNEXIN V WITH COAGULATION FACTORS X AND V IN PULMONARY EMBOLISM PATIENTS Aryan Mathur, Mira Nigudkar, Martin Lundy, Fakiha Siddiqui, Debra Hoppensteadt, Amir Darki, Jeanine Walenga, Jawed Fareed. Loyola University Stritch School of Medicine, Maywood, IL, USA |
||||
|
(604) FACTOR IIA INHIBITORS: MECHANISMS, CLINICAL COMPLICATIONS, AND ADVANCES IN REVERSAL STRATEGIES Parnika Tanguturu1, Fakiha Siddiqui2, Jawed Fareed2. 1Global Thrombosis Forum, Suwanee, GA, USA 2Loyola University, Chicago, IL, USA |
|||||
A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS | |||||
|
(605) FITUSIRAN: A NOVEL ANTITHROMBIN-TARGETING THERAPY FOR HEMOPHILIA A AND B, WITH OR WITHOUT INHIBITORS Mohammad Alashqar1, Milap Nahata1.2. 1Institute of Therapeutic Innovations and Outcomes, College of Pharmacy, The Ohio State University, Columbus, OH, USA 2College of Medicine, The Ohio State University, Columbus, OH, USA |
||||
|
(606) PREVALENCE OF SOCIAL NEEDS AND THEIR ASSOCIATION WITH HEALTHCARE UTILIZATION IN VON WILLEBRAND DISEASE Anika Dhingra1, Chengshi Jin1,2, Sophie Shean3, Zahara Jones3, Mary Lesh3, Katrina Unpingco3, Alison Matsunaga1,3, Shreya Agarwal1,3. 1School of Medicine, University of California San Francisco, San Francisco, CA, USA 2Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA 3Division of Hematology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA |
||||
|
(608) FRONTIER3: SAFETY AND EFFICACY OF MIM8 PROPHYLAXIS IN PEDIATRIC PATIENTS WITH HEMOPHILIA A Johnny Mahlangu1, M. Elaine Eyster2, Karin Fijn van Draat3, Gili Kenet4, Nita Radhakrishnan5, Irena Woznica-Karczmarz6, Runhui Wu7, Chur Woo You8, Andrea Paramo Florencio9, Jay Jay Thaung Zaw9, Emily Waters10, Manuel Carcao11, Niki Patel10. 1Department of Molecular Medicine and Haematology, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa 2Department of Medicine, Penn State College of Medicine, Hershey, PA, USA 3Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Pediatric Hematology, Amsterdam, Netherlands 4National Hemophilia Center, Sheba Medical Center, Tel HaShomer, Israel 5Department of Pediatric Hematology Oncology, Post Graduate Institute of Child Health, Noida, India 6Department of Transfusion Medicine, Children`s University Hospital, Lublin, Poland 7Department of Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China 8Daejeon Eulji Medical Center, Eulji University, Daejeon, Korea 9Novo Nordisk A/S, Søborg, Denmark 10Novo Nordisk, Inc., Plainsboro, NJ, USA 11Division of Hematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada |
||||
|
(609) FRONTIER5 DIRECT SWITCH STUDY: SAFETY OF INITIATING MIM8 PROPHYLAXIS WITHOUT WASHOUT OF EMICIZUMAB Johannes Oldenburg1, Gary Benson2, Pratima Chowdary3, Robert Klamroth1,4, Anne Lienhart5, Davide Matino6, Camila Martins Mazini Tavares7, Keiji Nogami8, Flora Peyvandi9,10, Amalie Rhode Høgh Nielsen7, Guy Young11, Emily Waters12, Allison P Wheeler13, Atish Patel12. 1Institute of Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany 2Department of Haematology, Belfast Health and Social Care Trust, Belfast, United Kingdom 3Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom 4Vivantes Klinikum im Friedrichshain, Berlin, Germany 5Unite d'Hemostase Clinique, Centre de Reference de l'Hemophilie, Hopital Louis Pradel, Lyon, France 6Department of Medicine, McMaster University, Hamilton, ON, Canada 7Novo Nordisk A/S, Søborg, Denmark 8Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan 9Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, 20122, Milan, Italy 10Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy 11Cancer and Blood Disease Institute, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA 12Novo Nordisk Inc., Plainsboro, NJ, USA 13Washington Center for Bleeding Disorders, Seattle, WA, USA |
||||
|
(610) NON-JOINT BLEEDS IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS: CONCIZUMAB EXPLORER7 STUDY Amy Shapiro1, Ana Boban2, Renée Brown Frandsen3, Giancarlo Castaman4, Kingsley Hampton5, Keiji Nogami6, Jameela Sathar7, Senthil Vel3, Jerzy Windyga8, Emily Waters9, Victor Jimenez Yuste10, Allison Duchman9. 1Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA 2Haemophilia Centre, Department of Haematology, University Hospital Centre Zagreb, Zagreb, Croatia and School of Medicine, University of Zagreb, Zagreb, Croatia 3Novo Nordisk A/S, Søborg, Denmark 4Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy 5Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom 6Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan 7Department of Haematology, Ampang Hospital, Kuala Lumpur, Malaysia 8Department of Haemostasis Disorders and Internal Medicine, Laboratory of Haemostasis and Metabolic Diseases, Institute of Haematology and Transfusion Medicine, 02-776, Warsaw, Poland 9Novo Nordisk Inc., Plainsboro, NJ, USA 10Department of Haematology, La Paz University Hospital Coagulopathies and Disorders of Haemostasis Group IdiPaz, Autónoma University, Madrid, Spain |
||||
|
(611) EVALUATION OF PLASMINOGEN ACTIVATOR INHIBITOR-1 IN END-STAGE RENAL DISEASE PATIENTS Riddhi Surve1, Charvi Chegireddy1, Fakiha Siddiqui 2, Jawed Fareed2, Vinod Bansal2. 1Global Thrombosis Forum, Suwanee, GA, USA 2Loyola University, Maywood, IL, USA |
||||
A7. PATHOPHYSIOLOGY OF THROMBOSIS | |||||
|
(612) EVALUATION OF C-REACTIVE PROTEIN IN END-STAGE RENAL DISEASE PATIENTS Neha Koganti1, Aarav Gupta1, Fakiha Siddiqui 2, Jawed Fareed2, Vinod Bansal2. 1Global Thrombosis Forum, Suwanee, GA, USA 2Loyola University, Maywood, IL, USA |
||||
|
(613) ENROLLMENT CHARACTERISTICS AND REAL-WORLD INSIGHTS INTO DISEASE BURDEN AND GIVOSIRAN TREATMENT IN PATIENTS WITH ACUTE HEPATIC PORPHYRIA IN THE ELEVATE REGISTRY Eliane Sardh1, David Cassiman2, Laurent Gouya3, Bruce Wang4, Weiming Du5, Desmond Murphy5, Teresa L. Kauf5, Jamie L. Weiss5, Manisha Balwani6. 1Porphyria Centre Sweden, Centre for Inherited Metabolic Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden 2Department of Gastroenterology-Hepatology and Center for Metabolic Diseases, University Hospital Leuven, Leuven, Belgium 3Centre Français des Porphyries, Paris, France 4University of California, San Francisco, CA, USA 5Alnylam Pharmaceuticals, Cambridge, MA, USA 6Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA |
||||
A8. ANTITHROMBOTIC THERAPY | |||||
|
(614) RIVAROXABAN AS SECONDARY THROMBOPROPHYLAXIS IN PEDIATRIC PATIENTS WITH DIGESTIVE MALABSORPTION Angela F Journell 1, Chelsea E. Peters1, Jessica Meznarich1,2, Sasidhar Goteti1,2. 1Primary Children's Hospital, Salt Lake City, UT, USA 2University of Utah, Salt Lake City, UT, USA |
||||
|
(615) EVALUATION OF APIXABAN DOSING PRACTICES FOR VTE/PE IN MEDICALLY COMPLEX PATIENTS Thalia Padilla Kelley1, Rebecca Pontius1, Aamna Khan2, Marie Piatski1, Eric Bleem1, Nancy Padilla-Lazos1, Jake Berkowitz1, Onyekachi Anya3, Robert Nixon1, Kevin Huang1, Corinne Lavasseur1, Joseph Shatzel1. 1Oregon Health & Science University, Portland, OR, USA 2Hillsboro Medical Center, Portland, OR, USA 3 Legacy Salmon Creek Medical Center, Portland, OR, USA |
||||
A9. INFORMATIONAL ABSTRACT (POSTER ONLY) | |||||
|
(616) REDUCED DOSE COMPARED TO STANDARD DOSE APIXABAN FOR VTE SECONDARY PREVENTION IN PATIENTS WITH ACTIVE CANCER Claire E. Burbridge, Tenley E. Ryan, Amanda R. Gillion. Lt. Col. Luke Weathers Jr. Veterans Affairs Medical Center, Memphis, TN, USA |
||||
|
(617) SURGERY IN THE EMICIZUMAB ERA: REAL-WORLD EVIDENCE FROM THE MID-ATLANTIC REGION Jan G. Kuhn1, Erika J. Martin1, Regina Butler2, Susan Gallagher2, Lisa Maiale-Howell2, J. Nathan Hagstrom3, Elle Levy4, Dyanne Morris5, Margy Sennett6. 1Virginia Commonwealth University, Richmond, VA, USA 2Children's Hospital of Philadelphia, Philadelphia, PA, USA 3Lehigh Valley Health Network, Allentown, PA, USA 4Children’s National Hospital, Washington, DC, USA 5University of Pennsylvania, Philadelphia, PA, USA 6University of Virginia, Charlottesville, VA, USA |
||||
|
(618) BRIDGING IN HIGH THROMBOEMBOLIC AND VENOUS THROMBOEMBOLISM RISK PATIENTS ON DIRECT ORAL ANTICOAGULANTS: IMPLICATIONS FOR ANTICOAGULATION STEWARDSHIP (BRAVO-HTV) Itea Thomallari1, Thaddaus R. Hellwig1,3, Shannon D. Wegleitner1, Amanda C. Owen1, Michael P. Gulseth1,2. 1Sanford USD Medical Center, Sioux Falls, SD, USA 2University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA 3South Dakota State University College of Pharmacy, Sioux Falls, SD, USA |
||||